Sunday, May 1, 2011

Alkem ties up with Swedish biotech firm Karo bio for a heterozygous familial hypercholesterolemia (HeFH drug

Alkem received exclusive rights to commercialize Karo Bio’s metabolic candidate eprotirome in India and other undisclosed Asia- Pacific and African markets. Alkem plans to conduct an Indian Phase III trial of the thyroid hormone receptor agonist to treat primary hyperlipidemia. Karo Bio will have access to the data from the Indian trial for use in its MAA submission in the EU for eprotirome to treat heterozygous familial hypercholesterolemia (HeFH). Karo Bio plans to start a Phase III trial in HeFH next quarter. Karo Bio, which is eligible for royalties, said the deal will reduce its estimated Phase III development costs for eprotirome by about SEK100 million ($16.4 million) to SEK300 million ($49.3 million).